References
[1] Nelofar Kureshi, Syed Sibte Raza Abidi, “A Predictive Model for Personalized Therapeutic Interventions in Non-small Cell Lung Cancer”, IEEE Journal of Health Informatics Vol. 20, No.1, pp. 424-431, 2016.
[2] PR Anisha, CKK Reddy, LVN Prasad, "A pragmatic approach for detecting liver cancer using image processing and data mining techniques", International Conference on Signal Processing And Communication Engineering Systems (SPACES), India, pp.1-6, 2015.
[3] F. J. Kaye, N. Lindeman, T. J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. J., W. R. Sellers, B. E. Johnson, M. Meyerson, “EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy”, Science, vol. 304, no. 5676, pp. 1497-1500, Jun. 2004.
[4] F. G. Haluska, D. N. Louis, D. C. Christiani, J. Settleman, D. A. Haber, “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib”, New England J. Med., vol. 350, no. 21, pp. 2129-2139, 2004.
[5] H. B. Kekre, A. Bild, E. S. Iversen, A. T. Huang, J. R. Nevins, M.West, “Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes”, Proc. Nat. Acad. Sci. vol. 101, no. 22, pp. 8431-8436, 2004.
[6] Nelofar Kureshi, L. X. Li, “Survival prediction of diffuse large-B-cell lymphoma based on both clinical and gene expression information”, Bioinformatics, vol. 22, no. 4, pp. 466-471, 2006.
[7] A. J. Stephenson, A. Smith, M. W. Kattan, J. Satagopan, V. E. Reuter, P. T. Scardino, W.L. Gerald, “Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy”, Cancer, vol. 104, no. 2, pp. 290-298, 2005.
[8] C. C. Bennett, T. W. Doub, R. Selove, “EHRs connect research and practice: Where predictive modeling, artificial intelligence, and clinical decision support intersect”, Health Policy Technol., vol. 1, no. 2, pp. 105-114, 2012.
[9] L. Chouchane, R. Mamtani, A. Dallol, J. I. Sheikh, “Personalized medicine: a patient-centered paradigm”, J. Trans. Med., vol. 9, Issue.1, pp.201-206, 2011.
[10] S. Navada, P. Lai, A. G. Schwartz, G.P. Kalemkerian, “Temporal trends in small cell lung cancer: Analysis of the national surveillance epidemiology and end-results (SEER) database”, J. Clin. Oncol., vol. 24, no. 18, p. 70-82, 2006.
[11] R. S. Herbst, M. Fukuoka, J. Baselga, “Gefitinib-A novel targeted approach to treating cancer”, Nature Rev. Cancer, vol. 4, no. 12, pp. 956-965, 2004.
[12] Movsas, A.L. Stiegler, T.J. Boggon, S. Kobayashi, B. Halmos, “EGFR-mutated lung cancer: A paradigm of molecular oncology”, Oncotarget, vol. 1, no. 7, pp. 497-514, 2010.
[13] Yasser M. Kadah, Einhorn LH, Bond WH, Hornback N, Joe BT, “Long-term results in combinedmodality treatment of small cell carcinoma of the lung”, Semin Oncol, Vol. 5, No. 3, pp. 309-313, 1978
[14] Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, “Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database”, J Clin Oncol, Vol.24, Issue.28, pp.4539-4544, 2006.
[15] Murray N, Turrisi AT, “A review of first-line treatment for small-cell lung cancer”, J Thorac Oncol, Vol.1, Issue.3, pp.270278, 2006.
[16] Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA., “The decrease in breast-cancer incidence in 2003 in the United States”, New England Journal of Medicine, Vol.356, Issue.16, pp.1670-1674, 2007.
[17] Green RA, Humphrey E, Close H, Patno ME, “Alkylating agents in bronchogenic carcinoma”, Am J Med, Vol.46, Issue.4, pp.516-525, 1969.
[18] Chung-Ming Wu, Weiss RB, “Small-cell carcinoma of the lung: therapeutic management”, Ann Intern Med, Vol.88, Issue.4, pp.522–31, 1978.
[19] Nelofar Kureshi, Syed Sibte Raza Abidi, “A Predictive Model for Personalized Therapeutic Interventions in Non-small Cell Lung Cancer”, IEEE Journal of Health Informatics Vol. 20, No.1, pp. 424-431, 2016.
[20] J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J., W.R. Sellers, B.E. Johnson, M. Meyerson, “EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy”, Science, vol. 304, no. 5676, pp. 1497-1500, 2004.
[21] D.C. Christiani, J. Settleman, D.A. Haber, “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib”, New England J. Med., vol.350, no.21, pp.2129-2139, 2004.
[22] C.M. Chen, A. Bild, E.S. Iversen, A.T. Huang, J.R. Nevins, M. West, “Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes”, Proc. Nat. Acad. Sci., vol.101, no.22, pp. 8431-8436, 2004.
[23] L. X. Li, “Survival prediction of diffuse large-B-cell lymphoma based on both clinical and gene expression information”, Bioinformatics, vol. 22, no. 4, pp. 466-471, 2006.
[24] A.J. Stephenson, A. Smith, M.W. Kattan, J. Satagopan, V.E. Reuter, P.T. Scardino, W.L. Gerald, “Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy”, Cancer, vol. 104, no. 2, pp. 290-298, 2005.
[25] C.C. Bennett, T.W. Doub, R. Selove, “EHRs connect research and practice: Where predictive modeling, artificial intelligence, and clinical decision support intersect”, Health Policy Technol., vol. 1, no. 2, pp. 105-114, 2012.
[26] L. Chouchane, R. Mamtani, A. Dallol, J.I. Sheikh, “Personalized medicine: a patient-centered paradigm”, J. Trans. Med., vol. 9, Issue.1, pp.201-206, 2011.
[27] S. Navada, P. Lai, A.G. Schwartz, G.P. Kalemkerian, “Temporal trends in small cell lung cancer: Analysis of the national surveillance epidemiology and end-results (SEER) database”, J. Clin. Oncol, vol.24, no.18, pp.70-82, 2006.
[28] R. S. Herbst, M. Fukuoka, J. Baselga, “Gefitinib—A novel targeted approach to treating cancer”, Nature Rev. Cancer, vol. 4, no. 12, pp. 956-965, 2004.
[29] Z. Zhang, A. L. Stiegler, T. J. Boggon, S. Kobayashi, B. Halmos, “EGFR-mutated lung cancer: A paradigm of molecular oncology”, Oncotarget, vol. 1, no. 7, pp. 497-514, 2010.
[30] Einhorn LH, Bond WH, Hornback N, Joe BT, “Long-term results in combinedmodality treatment of small cell carcinoma of the lung”, Semin Oncol, Vol.5, Issue.3, pp.309-313, 1978.
[31] Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, “Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database”, J Clin Oncol, Vol.24, Issue.28, pp.4539-44, 2006
[32] Murray N, Turrisi AT, “A review of first-line treatment for small-cell lung cancer”, J Thorac Oncol, Vol.1, Issue.3, pp.270-278, 2006
[33] Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ., “Cancer statistics”, CA Cancer J Clin, Vol.57, Issue.4, pp.43-66, 2007
[34] Green RA, Humphrey E, Close H, Patno ME, “Alkylating agents in bronchogenic carcinoma”, Am J Med, Vol.12, Issue.6, pp.516-525, 2007.